Evidence map›Paper›PMID 37182116›Full record

ArticleEuropean urology open science2023

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance.

Nikita Sushentsev, Luis Abrego, Anna Colarieti, Nimalan Sanmugalingam, Arnaldo Stanzione, Jeries Paolo Zawaideh, Iztok Caglic, Alexey Zaikin, Oleg Blyuss, Tristan Barrett

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Nikita SushentsevDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Luis AbregoDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Anna ColarietiDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Nimalan SanmugalingamDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Arnaldo StanzioneDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Jeries Paolo ZawaidehDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Iztok CaglicDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Alexey ZaikinDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Oleg BlyussWolfson Institute of Population Health, Queen Mary University of London, London, UK.
Tristan BarrettDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
University of Cambridge · GBUniversity College London · GBAddenbrooke's Hospital · GBOspedale Policlinico San Martino · ITQueen Mary University of London · GBUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global uptake of prostate cancer (PCa) active surveillance (AS) is steadily increasing. While prostate-specific antigen density (PSAD) is an important baseline predictor of PCa progression on AS, there is a scarcity of recommendations on its use in follow-up. In particular, the best way of measuring PSAD is unclear. One approach would be to use the baseline gland volume (BGV) as a denominator in all calculations throughout AS (nonadaptive PSAD, PSAD Patient summary: Repeat measurements of prostate-specific antigen (PSA) and PSA density (PSAD) are the mainstay of active surveillance in prostate cancer. Our study suggests that in patients with a prostate gland of 55 ml or smaller, PSAD measurements are a better predictor of tumour progression, whereas men with a larger gland may benefit more from PSA monitoring.

Indexed as

Active surveillanceArtificial intelligenceLongitudinal dataPredictive modellingProstate cancerProstate-specific antigenRecurrent neural networks

Identifiers

PMID37182116
PMCPMC10172696
OpenAlexW4367399885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.